ArticleTranslational lung cancer research2025
Effect of neoadjuvant
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RACK1 governs a dual metabolic switch in lung adenocarcinoma through c-Src/G6PD and TRIM21/LDHA Axes.Cell death & disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of neoadjuvant systemic therapy in limited-stage small cell lung cancer (SCLC) is unknown but promising. This real-world study aimed to investigate the prospects of applying neoadjuvant treatment in patients with resectable limited-stage SCLC. Methods: Patients diagnosed with stage I-III SCLC who underwent surgical resection of primary tumor were identified in the Surveillance, Epidemiology, and End Results (SEER) database (2007-2021). Survival outcomes were compared between neoadjuvant and adjuvant cohorts before and after matching. Multivariate Cox and Fine and Gray's competing risk regression models were built to identify prognostic factors and to adjust for covariates in subgroup analyses. Results: A total of 1,702 surgical resected SCLC were included in the study, among which 1,132 (67%) were treated with adjuvant therapy, while 55 (3%) received neoadjuvant therapy. Compared to adjuvant therapy, patients who received neoadjuvant therapy were significantly younger but exhibited more advanced tumor stages. In entire cohort, multivariate analyses showed that neoadjuvant therapy was independent favorable prognostic factor for overall survival (OS) [hazard ratio (HR) =0.69, 95% confidence interval (CI): 0.48-0.99, P=0.04]; however, the mortality reduction for lung cancer-specific survival (LCSS) was not significant [subdistribution hazard ratio (SHR) =0.83, 95% CI: 0.56-1.23, P=0.35]. Subgroup analyses indicated that patients with more advanced tumor stages tended to derive greater survival benefits from neoadjuvant systemic therapy. In matched cohort, neoadjuvant therapy was significantly associated with both improved OS (log-rank P=0.04) and LCSS (Fine and Gray's P=0.04) in stage III cohort. Conclusions: In the real world, neoadjuvant systemic therapy was associated with improved survival in surgical resected SCLC, especially for those with stage III disease. This indicates that neoadjuvant therapy might be a promising treatment modality for resectable locally advanced SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.